Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Merestinib dihydrochloride is an effective and orally bioavailable c-Met inhibitor (Ki=2 nM). It has anti-tumor activities and also has potent activity against MST1R (IC50=11 nM), FLT3 (IC50=7 nM), AXL (IC50=2 nM), MERTK (IC50=10 nM), TEK (IC50=63 nM), ROS1, DDR1/2 (IC50=0.1/7 nM) and MKNK1/2 (IC50=7 nM).
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 591 | 5日内发货 | ||
5 mg | ¥ 997 | 5日内发货 | ||
25 mg | ¥ 4,220 | 8-10周 | ||
50 mg | ¥ 5,490 | 8-10周 | ||
100 mg | ¥ 8,320 | 8-10周 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,490 | 5日内发货 |
Merestinib dihydrochloride 的其他形式现货产品:
产品描述 | Merestinib dihydrochloride is an effective and orally bioavailable c-Met inhibitor (Ki=2 nM). It has anti-tumor activities and also has potent activity against MST1R (IC50=11 nM), FLT3 (IC50=7 nM), AXL (IC50=2 nM), MERTK (IC50=10 nM), TEK (IC50=63 nM), ROS1, DDR1/2 (IC50=0.1/7 nM) and MKNK1/2 (IC50=7 nM). |
靶点活性 | FLT3:7 nM, TEK:63 nM, MerTK:10 nM, MST1R:11 nM, MKNK1/2:7 nM, DDR1/2:0.1/7 nM, Axl:2 nM, c-Met:(ki)2 nM |
体外活性 | Merestinib demonstrates the effects on MET pathway-dependent cell scattering and cell proliferation. The mean IC50 value (n=6 determinations) of Merestinib for inhibition of MET auto-phosphorylation in HGF-stimulated H460 cells is 35.2±6.9 nM and the IC50 for MET auto-phosphorylation in S114 cells is 59.2 nM. Merestinib also inhibits MST1R (IC50=11 nM), AXL (IC50=2 nM), MERTK (IC50=10 nM), TYRO3 (IC50=28 nM), ROS1, PDGFRA (IC50=41 nM), FLT3 (IC50=7 nM), TEK (IC50=63 nM), DDR1/2 (IC50=0.1/7 nM) and MKNK1/2 (IC50=7 nM)[1]. Merestinib (2, 5, and 10 μM) decreases the number of viable TFK-1 and SZ-1 cells in a dose and time-dependent manner, and significant inhibits wound healing for TFK-1 and SZ-1 cell lines. Transfection with the MET variants confers growth-factor independence and treatment with Merestinib inhibits the growth of these MET variant clones with an IC50 ranging from 3-fold more potent (V1092I) to approximately 6-fold less potent (L1195V) compare with the growth inhibition of cells with the MET wild-type sequence[1]. Merestinib inhibits cell invasion in TFK-1 and SZ-1 cells in a concentration-dependent manner[2]. |
体内活性 | Merestinib is a type-II ATP competitive, slow-off inhibitor of MET tyrosine kinase with a pharmacodynamic residence time (Koff) of 0.00132 min-1 and t1/2 of 525 min. Merestinib (20 mg/kg) decreases TFK-1 tumor growth significantly relative to vehicle control. Merestinib treatment inhibits MET phosphorylation with a composite TED50 (50 % target inhibition dose) of 1.2 mg/kg and a composite TED90 (90 % target inhibition dose) of 7.4 mg/kg[1]. Merestinib inhibits the growth of intra- and extrahepatic CCC xenograft tumors[2]. Merestinib demonstrates anti-tumor effects in MET amplified (MKN45), MET autocrine (U-87MG, and KP4), and MET over-expressed (H441) xenograft models; and in vivo vessel normalization effects. |
别名 | LY2801653 dihydrochloride |
分子量 | 625.45 |
分子式 | C30H24Cl2F2N6O3 |
CAS No. | 1206801-37-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (159.88 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.5988 mL | 7.9942 mL | 15.9885 mL | 39.9712 mL |
5 mM | 0.3198 mL | 1.5988 mL | 3.1977 mL | 7.9942 mL | |
10 mM | 0.1599 mL | 0.7994 mL | 1.5988 mL | 3.9971 mL | |
20 mM | 0.0799 mL | 0.3997 mL | 0.7994 mL | 1.9986 mL | |
50 mM | 0.032 mL | 0.1599 mL | 0.3198 mL | 0.7994 mL | |
100 mM | 0.016 mL | 0.0799 mL | 0.1599 mL | 0.3997 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Merestinib dihydrochloride 1206801-37-7 Cell Cycle/Checkpoint Cytoskeletal Signaling Stem Cells ROCK LY-2801653 Dihydrochloride LY2801653 Dihydrochloride Merestinib LY-2801653 LY2801653 LY 2801653 Dihydrochloride LY2801653 dihydrochloride LY 2801653 Merestinib Dihydrochloride Inhibitor inhibitor inhibit